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Title: Improving Outcomes for Older women with Gynaecological 
Malignancies 
 
Abstract 
The incidence of most gynaecological malignancies rises significantly with 
increasing age. With an ageing population, the proportion of women over the age 
of 65 with cancer is expected to rise substantially over the next decade. 
Unfortunately, survival outcomes are much poorer in older patients and evidence 
suggests that older women with gynaecological cancers are less likely to receive 
current standard of care treatment options. Despite this, older women are under-
represented in practice changing clinical studies.  The evidence for efficacy and 
tolerability is therefore extrapolated from a younger; often more fit population and 
applied to in every day clinical practice to older patients with co-morbidities. 
There has been significant progress in the development of geriatric assessment 
in oncology to predict treatment outcomes and tolerability however there is still 
no clear evidence that undertaking a geriatric assessment improves patient 
outcomes.  Clinical trials focusing on treating older patients are urgently required. 
In this review, we discuss the evidence for treatment of gynaecological cancers 
as well as methods of assessing older patients for therapy. Potential biomarkers 
of ageing are also summarised. 
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Introduction 
 
i) Incidence and survival in older patients 
 
The EUROCARE project [1], which assesses cancer survival across Europe over 
time, demonstrated that although for almost all cancers there was a continued 
improvement in outcomes over time, the rate of progress was slower in older 
patients - in particular for patients with gynaecological malignancies [2]. 
However, of note, if older patients with a gynaecological cancer survived the first 
year after diagnosis, the prognosis for this group was similar to middle-aged 
patients [2]. 
 
The majority of gynaecological cancers (ovarian, endometrial, vulval) are 
diagnosed in postmenopausal women [3-5]. For cervical cancer, in addition to 
the incidence peak at age 30-34, there is a second rise in incidence above the 
age of 70 [6].  The incidence of endometrial cancer peaks in the 70 - 74 age 
group (94.1 per 100,000). Between 1993 and 2009, the incidence of endometrial 
cancer in women over the age of 75 rose by 43% [4, 7] and two thirds of deaths 
from endometrial cancer occur in women over the age of 70 [4].   
 
Ovarian cancer is predominantly a disease of older women; in the UK, around 
half of all diagnoses are in women over the age of 65 [8] and the median age at 
diagnosis is 64.7 [9].  This is similar in the USA where 44% of all ovarian cancer 
cases occur in women over the age of 65 and the median age at diagnosis of 63 
[10]. Over the past 20 years, significant advances in the management of ovarian 
cancer have led to the improved survival rates in all groups with the notable 
exception of those over the age of 80 [1]. For example, in the UK, the mean 1-
year survival for stage IV ovarian cancer patients of all ages is 51.0% but this 
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dramatically falls to 35.7% for women over the age of 70 [11]. The fundamental 
issue of worsening outcomes with increasing age is applicable worldwide [12].   
 
With an ageing population, although the overall incidence of cancer is not 
projected to change, the proportion of patients over the age of 65 is expected to 
rise. For example, in the UK by 2030, 67.5% of all female cancer patients will be 
over the age of 65 [7]. The UK survival statistics for gynaecological malignancies 
are known to be poorer compared to the results of other developed countries. Of 
concern, is the fact that this difference is magnified further for older patients [11].  
For example, a woman over the age of 70 diagnosed with stage III ovarian 
cancer in Canada has an expected 1-year survival of 74% compared to just 57% 
in the UK [11].    
 
ii) Potential reasons for poor survival 
 
The reasons for poorer outcomes in older patients with gynaecological cancers 
are not fully understood. It has been postulated that delayed presentation for a 
multitude of psychosocial reasons leading to advanced stage at diagnosis, 
increasing comorbidities, relative under-treatment as well as potentially adverse 
tumour biology in cancers diagnosed in older women may all play a role.  
 
A report from the International Cancer Benchmarking Group demonstrated that 
more advanced stage at ovarian cancer diagnosis was associated with 
increasing age [9, 11].  Furthermore, it has been shown that older patients were 
significantly less likely to be referred for investigations such as abdominal 
ultrasound or to a gynaecologist in the year preceding a diagnosis of ovarian 
cancer [13].  One study reported that the median time for a 75-year old woman to 
be referred for further investigation following the reporting of symptoms was 20 
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weeks [13]. Older women with endometrial cancer are more likely to be 
diagnosed with a later stage and present as an emergency, both factors known 
to be associated with worse outcomes [14]. 
 
The treatment plan for older women is often different compared to younger 
patients. For example, older patients with cervical cancer are more likely to 
receive primary radiotherapy rather than surgery, less likely to undergo a radical 
hysterectomy, lymphadenectomy, adjuvant radiotherapy or brachytherapy [15, 
16].  In advanced disease, 12.1% of patients over 80 years old compared to 
3.9% under 50 years old (p<0.0001) received no anticancer treatment.  Adjusting 
for stage and treatment, disease-specific mortality was increased in those over 
the age of 70 [16]. Evaluation of data from the SEER database (1992 and 2002) 
demonstrated that women over the age of 65 were less likely to undergo radical 
surgery for endometrial cancer [17].  A retrospective study of 20,468 women 
from the USA National Cancer Database demonstrated that, adjusting for 
prognostic factors, women between the age of 75 and 84 were less likely to 
receive surgery, radiotherapy and chemotherapy than women under the age of 
55 for high-grade endometrial cancer [18].  Similar findings were found from an 
analysis of three GOG studies which showed that only 64% of patients over the 
age of 70 who were offered adjuvant radiotherapy actually went on to receive 
treatment [19]. 
 
Although there have been international efforts to increase the recruitment of 
older patients into clinical studies, women over the age of 65 remain 
underrepresented in practice-changing studies [20-22] and yet form a significant 
proportion of patients being treated in daily clinical practice. For example, among 
28,766 patients enrolled into 55 registration studies in the US across a number of 
malignancies including ovarian cancer, 35% of the study population were over 
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the age of 65 compared with 60% in the US population in clinical practice [20].  
The discrepancy increases with age; with the exception of hormonal therapy 
trials in breast cancer, only 4% of patients over the age of 75 entered clinical 
trials.  For example, in the pivotal GOG-158 phase trial which contributed to the 
establishment of carboplatin in combination with paclitaxel as standard care for 
first-line treatment in ovarian cancer, 11% of the patients enrolled were over the 
age of 71 and only 1% over the age of 81 [49]. There is a lack of prospective 
clinical studies focusing on older, less fit patients with gynaecological 
malignancies. 
  
Finally, it has been recognised that there is a need for an alternative assessment 
method to guide treatment decisions in the older population. Eastern 
Cooperative Oncology Group (ECOG) Performance Status (PS) is the accepted 
standard for evaluation of a patient’s functional status both in clinical studies and 
in routine clinical practice.  It is widely accepted that this is a limited tool for 
assessment of older patients and does not accurately represent limitations in 
functional or cognitive capability [23-25].   
 
In the remainder of this review, the evidence for treatment of gynaecological 
cancers in older women, methods of assessing older patients for cancer therapy 
and potential steps towards improving outcomes are discussed. 
 
 
Endometrial and Cervical Cancer 	
Studies addressing the management of older patients with endometrial and 
cervical cancer are limited and largely consist of retrospective cohort analyses.   
The Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC) 1 
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trial showed that women over the age of 60 were threefold more likely to have a 
locoregional recurrence following radical surgery compared to younger patients 
(HR 3.90 p=00017) [26]. Following 15-year follow-up, the local recurrence rate in 
the overall study population was reduced from 15.5% to 6.0% with the addition of 
post-operative external beam radiotherapy (EBRT).  However, in older patients 
who may have co-morbidities and/or functional limitations, the potential treatment 
toxicities (primarily bladder and bowel) as well as the need for a daily treatment 
over 5 weeks needs to be considered. The PORTEC-2 trial in which almost half 
of the patients were over the age of 70, high-dose rate (HDR) brachytherapy was 
shown to be equivalent to EBRT for local control in intermediate-high risk 
disease with a more tolerable toxicity profile in terms of gastrointestinal side 
effects [27].  
  
A retrospective case series of 113 women over 70 years old (median age 76) 
who received brachytherapy for stage I-IV cervical cancer reported grade III/IV 
rectal, small bowel and urinary tract toxicities rates in 1.8%, 0.9% and 2.7% of 
patients respectively.  The 3-year disease-specific survival was 81% [28].  A 
retrospective study from Japan evaluated outcomes according to age. 132 of the 
727 women whom received radical radiotherapy were over 75 years old. In this 
case series, there was no significant difference in late radiation bladder toxicity 
between patients aged ≤64, 65-74 and ≥75 years old. There appeared to be 
lower rectal toxicity in the over 75 year old patients group but this may be a 
reflection of the lower radiation dose delivered in this group (median dose 45Gy 
compared to 53Gy in those under the age of 64).  The 5 and 10-year disease-
specific survival rates were not significantly different between the three groups 
[29].  
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To date, there have been no prospective studies focusing on treatment tolerance 
and outcomes in older women with endometrial cancer or cervical cancer. 
Prospective studies including geriatric assessment to evaluate treatment 
outcomes and tolerability of chemotherapy and radical treatment options such as 
external beam radiotherapy, brachytherapy and radical hysterectomy specifically 
in older patients are required.  
 
Ovarian cancer 
The majority of reports related to older women with gynaecological cancers have 
focused on ovarian cancer. 
(i) Surgery  
 
Achieving optimal cytoreduction remains the most significant prognostic factor for 
ovarian cancer survival [30].  It has been consistently shown that increasing age 
is associated with lower rates of referral to oncology specialists, lower rates of 
cytoreductive surgery and lower rates of optimal cytoreduction [31-34]. 
Neoadjuvant chemotherapy (NACT) with interval debulking surgery has been 
shown to be associated with higher rates of optimal cytoreduction, lower 
perioperative morbidity and mortality rates than primary debulking surgery[35, 
36]. Although the use of NACT remains a highly debated topic, it is generally 
accepted that NACT maybe a preferable approach for more frail patients 
including older women who often present very unwell with concurrent medical 
conditions.  
 
Preoperative assessments have been studied to identify patients with higher 
perioperative morbidity and mortality. A review from the USA of over 1000 
patients demonstrated that 30-day death and serious morbidity rates rose 
significantly over the age of 60 and was independently associated with a number 
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of pre and peri-operative factors such as pre-operative weight loss, 
hypoalbuminaemia, prolonged operative time, need for transfusion or 
splenectomy and contaminated wound [37].  A large-single centre study 
evaluated the predictive ability of the age-adjusted comorbidity index (ACCI) for 
peri-operative complications, progression-free survival (PFS) and overall survival 
(OS) following cytoreductive surgery for ovarian cancer. The ACCI incorporates 
age into the Charlson-Comorbidity index, a validated score to predict 1 year-
mortality comprising of 19 medical comorbidities. Taking into consideration 
stratification for surgical complexity, an ACCI score of 0-1 (low risk) was 
significantly associated with complete cytoreduction (0–1=44%, 2–3=32%, 
≥4=32%; p=0.02).   The ACCI was predictive for PFS and OS but not for rates of 
minor or major perioperative complications [38].   
 
A retrospective analysis of all patients undergoing primary cytoreductive surgery 
from three tertiary cancer centres in the USA concluded that a high-risk group 
could be identified. Age > 75 was one of the factors defining this group as well as 
high tumour dissemination/stage IV disease, poor performance status as 
assessed by ASA score (American Society of Anesthesiologists) and poor 
nutrition (Albumin < 3.0g/dl). The median overall survival was 17 months in this 
group (n=38) compared to 40.2 months in the overall study population (n=576) 
with stage III and IV disease [39].   
 
 
(ii) Chemotherapy  
 
A relatively limited number of retrospective subgroup analyses have been 
performed to evaluate the outcomes of older patients receiving chemotherapy. 
For example, in a retrospective analysis of the phase 3 AGO-OVAR 3 study 
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(Carboplatin/Paclitaxel compared to Cisplatin/Paclitaxel in the first-line setting 
following cytoreductive surgery for advanced ovarian cancer), 103 patients over 
the age of 70 were compared to the under 70 years group (n=676). Over 80% of 
the patients in this analysis were ECOG PS 0 or 1 and the mean age of patients 
over 70 was 73.5 (range 70-85). The authors concluded that combination 
chemotherapy was tolerable in an older population but discontinuation rates 
were double in those over the age of 70 compared to the <70 group [40]. The 
reason for this remains unclear; toxicity rates, except fatigue, did not differ 
significantly between younger and older patients.  Quality of life assessments 
were undertaken and comparable between the two groups.   The authors 
suggest that there may be a difference in the attitude of investigators when 
treating older patients with a tendency towards treatment cessation in the event 
of toxicity rather than treatment delays and instituting supportive care measures 
in older patients [40].  This could impact on survival of older patients as was 
recently reported in a retrospective analysis of 184 patients receiving platinum 
with or without taxane-based chemotherapy for stage II to IV epithelial ovarian 
cancer. In this study, dose delays but not dose reductions were independently 
associated with a reduced overall survival in older patients [41].  Another 
retrospective study showed that reduced-dose carboplatin and paclitaxel was 
better tolerated in patients over the age of 70 than standard dosing and did not 
result in a statistically significant difference in overall survival (OS 41 months in 
the lower dose group versus 44 months in the standard dose group p=0.451) 
[42].  
 
The MITO-5 trial [43] prospectively addressed first-line dose-dense weekly 
carboplatin (AUC 2) and paclitaxel (60 mg/m2) in women ≥70 years and 
concluded that this approach is a safe and reasonably well-tolerated regimen in 
older women with 65% of the patients receiving all six cycles. The MITO-7 
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subsequently compared weekly carboplatin and paclitaxel to the established 
standard 3 weekly regimen as first-line treatment [44]. There was no significant 
difference in overall survival. However, the trend towards improved progression-
free survival with weekly chemotherapy appeared greater in those over the age 
of 70.  
 
In the recurrent disease setting, a sub-analysis of older patients within the 
CALYPSO trial that compared carboplatin in combination with liposomal 
doxorubicin to carboplatin in combination with paclitaxel in platinum-sensitive 
ovarian cancer was undertaken [45].   Overall, patients ≥70 (n=157 (16%)) 
experienced a higher rate of ≥ grade 2 sensory neuropathy (24.4% versus 
15.5%, P = 0.007) compared to younger patients.  Rates of haematological 
toxicities did not differ between the age groups. Interestingly, ≥ grade 2 allergic 
reactions were less frequent in older patients than those less than 70 years old 
(13.9% versus 5.8%, P = 0.005).  Older patients completed planned treatment as 
frequently as younger participants and there was no significant difference in 
median PFS between older and younger patients. Quality of life did not 
significantly differ according to age. The carboplatin/liposomal doxorubicin 
combination was associated with less toxicity than carboplatin in combination 
with paclitaxel (alopecia, sensory neuropathy, arthralgia/myalgia, febrile 
neutropenia) in older women. However, it is important to note that around 95% of 
patients 70 years old or over had a PS of 0 or 1 and therefore the applicability of 
these results to older patients in clinical practice who may have a worse 
performance status are unclear. 
 
 
(iii) Targeted therapies 
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Bevacizumab 
Bevacizumab, an anti-VEGF monoclonal antibody, which targets angiogenesis, 
has EMA approval in combination with chemotherapy as first-line treatment 
ovarian cancer, for recurrent (platinum-sensitive and platinum-resistant) ovarian 
cancer. In both phase III ovarian cancer studies of bevacizumab in combination 
with chemotherapy followed by maintenance treatment in the first line setting, 
ICON7 [46] and GOG 218 [47], patients were younger than average. In the 
ICON7 trial, the median age was 57 and recruitment was limited to patients with 
ECOG PS 0 or 1. There is currently no published data regarding outcomes and 
toxicities in the older population within this study. In the GOG 218 trial which 
included patients with ECOG PS 2, the median age was 60 (range 22-89) and 
23% of patients were over the age of 70. The improvement in PFS reported in 
GOG218 with the addition of bevacizumab was also seen in patients over the 
age of 70.  
 
In the OCEANS trial, a phase III study which demonstrated that the addition of 
bevacizumab to carboplatin in combination with gemcitabine followed by 
maintenance therapy improved PFS for first platinum–sensitive relapse, no 
significant difference in PFS between women aged above (35% of patients, 
n=85) and below 65 in the bevacizumab arm (12.3 and 12.5 months respectively) 
was noted [48]. To date, there has been no subset analysis of treatment 
tolerance according to age published.  Post-hoc exploratory efficacy and safety 
analyses were performed in patients ≥65 years (37% of patients, n=133) 
compared to those <65 in the AURELIA trial which assessed the addition of 
bevacizumab to investigator’s choice of chemotherapy in platinum-resistant 
ovarian cancer [49] . Significant benefits from the addition of bevacizumab in 
terms of PFS and response rate were seen in both older patients and the 
younger group (PFS hazard ratio <65 years 0.49; ≥65 0.47). There were no 
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major differences in toxicities according to age other than hypertension: ≥ grade 
2 hypertension was higher in the ≥ 65 years group compared to <65 in the 
bevacizumab-treated arms (31% vs. 13%). In addition, hypertension at baseline 
prior to trial therapy was also more frequent in patients ≥ 65 than <65 years (46% 
vs. 13%)[49].  The OCTAVIA[50] trial, a single-arm study which evaluated the 
addition of bevacizumab to 3 weekly carboplatin and weekly paclitaxel 
(80mg/m2), included 20% and 9% of patients over the age of 65 and 70 
respectively. The median PFS was 20.5 months in the ≥65s (n=37) compared to 
24.4 months in the <65 group (n=152) (95% CI 17.8-20.1 months) [51].  The 
incidence of grade ≥3 bleeding was higher in older patients (3% vs. 0%, 
respectively) [50].  In keeping with the AURELIA subgroup analysis, 
hypertension at baseline and on treatment was higher in the ≥65s [52]. 
 
Hypertension rates reported so far are higher in older patients receiving 
bevacizumab. This should not necessarily preclude older patients being 
considered for this treatment option however careful monitoring and treatment of 
hypertension prior to commencing and during bevacizumab therapy is required. 
This is particularly relevant for an older population in which ischaemic heart and 
cerebrovascular disease is not uncommon. A meta-analysis of phase 3 studies 
with bevacizumab in both the first-line and relapse ovarian cancer failed to 
demonstrate an improvement in PFS in women over 70 (HR: 0.74, CI: 0.54 to 
1.02; P = 0.067) [53]. This finding needs to be interpreted with caution given the 
relatively low numbers and nature of the analysis but clearly further studies, 
specifically targeting older, patients with co-morbidities are required.  A study is 
due to open of first-line Bevacizumab in patients over the age of 70 with 
advanced ovarian cancer (NCT02393898).   
 
PARP inhibitors 
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PARP inhibitors have shown significant clinical activity in women with BRCA-
mutated ovarian cancer and also in a proportion of patients with sporadic high-
grade serous ovarian cancer. In the pivotal study that led to the approval of 
maintenance olaparib in Europe for women with platinum-sensitive ovarian 
cancer that harbour a BRCA mutation (germline or somatic), 23% (n=17) of the 
BRCA-mutated cohort and 47% (n=27) of the non-BRCA group that received 
olaparib were ≥ 65 years and the oldest patient in the BRCA-mutated group was 
89 years old [54].  Although more commonly found in younger women, it is 
evident that BRCA mutations have been identified in patients over the age of 65 
[54-56].  Thus far, data on the tolerability and efficacy of PARP inhibitors in the 
older population have not been presented.  Although PARP inhibitors are better 
tolerated than chemotherapy, toxicities such as fatigue, nausea, neutropenia and 
anaemia if severe or mild but prolonged, may impact significantly on the 
functional capacity and quality of life of older patients.  PARP inhibitors have also 
been shown to increase the risk of myelodysplasia [57], potentially of increased 
relevance in an older population. Long-term follow up of PARP inhibitor studies 
will help address this issue.  In addition, given the current licensed dose and 
formulation of olaparib, patients receive 16 capsules per day; support for older 
patients who are likely to also be taking multiple other medications is important 
for treatment compliance. 
 
Geriatric Assessments in Oncology  
 
(i) Comprehensive Geriatric Assessment (CGA) 
Comprehensive geriatric assessment (CGA) is a multi-systems review of frailty, 
comorbidities, geriatric syndromes, mental health, functional difficulties and 
social circumstances.  It is a four-part clinical process of screening, assessment, 
intervention and follow-through [58] which has been shown to detect more co-
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morbidities and functional issues than the standard oncological assessment of 
performance status [23, 59]. In non-oncological settings, CGA has been shown 
to improve function and quality of life [60-62].  In cancer care, CGA has also 
been shown to predict treatment tolerance[63] and overall survival in a number of 
tumour types[25, 64]. 
 
The term CGA has sometimes been used inaccurately in oncology studies 
describing screening or assessment capacity rather than also including geriatric 
interventions and follow-through. The International Society of Geriatric Oncology 
(SIOG) Consensus Guidelines recommend the use of the term Geriatric 
Assessment (GA) in future research and publications to describe screening and 
assessment of older patients [64].  Oncological studies utilising and assessing 
the implementation of GA thus far have been fairly heterogeneous with no clear 
agreement on the essential parameters that should be included in a GA to 
assess older patients with cancer. Over a decade ago, SIOG recommended that 
a CGA-based approach should be utilised to improve the detection of 
comorbidities and that follow-up of deficits identified be included in any form of 
CGA intervention [65].  The SIOG consensus on geriatric assessment states that 
the key domains in a GA considered to be important are: functional status, 
fatigue, comorbidities, cognitive impairment and mental health status, social 
support, nutrition and the presence of geriatric syndromes such as falls.  To date, 
there is no one GA tool that has been recommended over another to reliably 
predict tolerance to cancer therapy or clinical outcomes [64].  It may well be that 
there is no one tool that is all encompassing for every tumour type and treatment 
modality. 
 
(ii) Examples of Geriatric assessment tools 
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Geriatric assessment in the oncological literature has taken a variety of forms 
including patient-completed questionnaires, healthcare professional-led 
questionnaires and a combination of both.  Biological factors such as 
hypoalbuminaemia, haemoglobin levels and estimated glomerular filtration rate 
have sometimes been included. The time it takes to perform a GA in the 
oncology setting is a practical issue and hence there has been much interest in 
the development of abbreviated and screening tools.   For example, it has been 
shown that the questions from the full activities of daily living (ADL) and 
instrumental activities of daily living (IADL) assessments can be condensed from 
a total of 18 to 6 questions and still recognise 98% of those who had a deficit 
identified from the full questionnaire [66]. 
 
A comprehensive review of all GA tools that have been tested in oncology is 
beyond the scope of this review and has previously been published [64, 67]. 
Table 2 summarises the key features of the most well described tools used in 
cancer patients and a selection are briefly described below. 
  
In one of the largest prospective studies undertaken, Hurria et al prospectively 
assessed the predictive value of a number of geriatric assessment variables for 
chemotherapy toxicity [63].  500 patients were assessed with a median age of 
73. 17% of the patients included had a gynaecological malignancy.  The 
assessment consisted of the physician evaluated Karnovsky Performance Status 
(KPS), “Timed up and Go” (a measure of functional status) and a cognitive test.  
Patients also completed a geriatric-assessment questionnaire evaluating 
functional status, medical comorbidities, mental state, social activity, social 
support and nutrition assisted by a healthcare professional when necessary.  An 
11-point model (CARG) was derived from evaluation of risk factors associated 
with severe toxicity combined with factors also considered to be important such 
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as chemotherapy dosing (summarised in Table 2). A “high-risk” score was 
associated with 83% grade 3 or 4 toxicity compared to 30% for a “low-risk” score, 
highlighting a substantial, clinically relevant rate of severe treatment-related 
toxicity even in a “low-risk” elderly population.  Of note, physician-evaluated KPS 
was not shown to correlate with risk of chemotherapy toxicity.   
 
The G8 score was evaluated as a screening tool to identify older patients who 
may benefit from a full CGA in a prospective study that included 364 patients 
with solid malignancies over the age of 70 [68].  G8 consists of a brief 
questionnaire of 8 questions (7 of which are derived from the mini nutritional 
assessment (MNA)) with each individual score ranging from 0 to 2 and a total 
maximal score of 17.  A cut-off value of 14 or less was identified as providing 
reasonable sensitivity for requiring a full CGA.  In the most recent SIOG 
recommendations, G8 was evaluated as one of the most reliable and sensitive of 
the screening tools available [69] to predict the need for a full CGA.  
 
 
(iii) The impact of geriatric assessment on decision-making and treatment 
outcomes 
 
Although Geriatric Assessment Tools can identify deficits that may not have 
been picked up in a routine oncological assessment, the impact of the additional 
information provided on treatment decision-making and more importantly, 
improving outcomes for older cancer patients is difficult to assess and not fully 
established [65].   
 
In a prospective pilot, of 168 patients with gastrointestinal or lung cancer over the 
age of 70 deemed eligible for CGA, only 29% were referred for assessment. 
	 18	
CGA altered the existing treatment plan in 1 out of 24 patients and influenced 
decision-making in a further 5 out of 6 patients whom did not have a 
management plan at the time of referral [70].  In a prospective study that 
included 937 cancer patients over the age of 70, GA was undertaken prior to the 
commencement of either first line or treatment at relapse. In 56% of patients, the 
GA was consulted before making a treatment decision but in only 6.1% did the 
GA further influence the treatment decision suggesting that clinical assessment 
by the treating oncologist remains dominant in the decision-making process in 
the majority of cases [71].  In contrast, in a cohort study of 161 older men and 
women (mean age 82.4), GA influenced treatment decisions in 49% of cases.  
For 57% of these patients, the change was to increase intensity of therapy [72].  
A similar pilot study undertaken in France of 105 patients with a median age of 
79 demonstrated that the results of a GA consisting of a screening questionnaire 
undertaken by an oncologist with geriatric training influenced the treatment 
decision in 38.7% of patients [73].   
 
Kalsi et al undertook a prospective cohort-controlled study of patients over the 
age of 70 being considered for systemic therapy for solid-organ malignancies 
[74]. All patients completed a screening questionnaire (CGA-GOLD) and a 
quality of life (QoL) questionnaire (EORTC-QLQ-C30).  In the intervention arm 
(n=65), patients considered high-risk (1 or more active comorbidity, CGA deficit, 
significant QoL or functional difficulty) received geriatrician-led CGA.  70.7% 
patients were assigned to CGA in the intervention arm. As a result, the mean 
number of interventions was 6.6. In the intervention arm, 33.8% of patients 
completed chemotherapy as planned compared to 11.4% in the control arm 
(p=0.0006) with a non-significant trend towards reduced grade 3 toxicity in the 
intervention arm (43.8% versus 52.9% in the control arm (P = 0.292).  This study 
was not powered to detect a survival benefit from CGA intervention but was the 
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first study to demonstrate a benefit from the use of CGA in terms of 
chemotherapy tolerance. The majority of patients included in this study were 
undergoing treatment for a gastrointestinal malignancy. It is not known whether 
this approach would be implementable and successful in gynaecological cancers 
but is worthy of consideration.  In a phase IIIl study of patients over the age of 70 
with stage IV non-small cell lung (n=494), patients were randomized to treatment 
allocation according to standard assessment using age and ECOG performance 
status or according to the outcome of a cancer physician-led CGA.  The primary 
outcome was treatment failure-free survival (TFFS) with secondary endpoints of 
OS, PFS, tolerability and quality of life.  According to the outcome of the CGA, 
patients were classed as fit, vulnerable or frail.  Frail patients received best 
supportive care where fit patients received a platinum-doublet (according to 
histological subtype) and vulnerable patients received single-agent Docetaxel.  
No significant difference was found between either group in either TFFS, PFS or 
OS.  The CGA group experienced less toxicity and improved treatment-
tolerability however (treatment failure due to toxicity 4.8 vs. 11.8%, P=0.007).  
Crucially this study did not involve any form of intervention to address issues 
identified in the CGA[75]. 
 
(iv) Studies incorporating Geriatric Assessments in Gynaecological 
Malignancies 
 
Both surgical and medical studies of GA specifically in gynaecological cancers 
have been limited.  The largest surgical retrospective review in ovarian cancer 
assessed 751 patients over an 8-year period who underwent primary 
surgery[76].  The rate of major complications (as defined by a grade 3-5 
complication on the validated clavien-dindo classification) was 16.4%. Ascites, 
pre-operative hypoalbuminaemia, raised white cell count and raised serum 
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creatinine were all associated with an increased likelihood of a major post-
operative complication.  The authors propose a predictive model of post-
operative complications in older patients following primary cytoreductive surgery 
based on the above, also including smoking status, ethnicity, haematocrit and 
platelet count. Prospective validation studies are necessary and application of a 
similar approach to NACT and interval debulking surgery would be useful.  
A prospective study which addresses whether a pre-operative risk stratification 
score (GA-GYN) collated from a number of geriatric variables collected at 
baseline will predict for perioperative morbidity in patients over the age of 70 who 
are planned to receive primary cytoreductive surgery for epithelial ovarian cancer 
is currently recruiting (NCT02315469). 
 
PACE, a pre-operative assessment tool in elderly cancer patients is an approach 
recommended by SIOG for adoption in routine clinical practice[77].  A study of 
460 consecutive patients over the age of 70 undergoing elective cancer surgery 
for a variety of solid organ tumours was undertaken to assess the predictive 
capability of a complete geriatric assessment. The geriatric tools used at 
baseline were MMSE, ADL, IADL, GDS, BFI (brief fatigue inventory), ECOG PS, 
ASA and Satariano’s index of comorbidities. IADL, moderate to severe BFI, 
abnormal ECOG PS (>1) predicted 30-day morbidity and mortality[77]. Of note, 
the full assessment undertaken by a specialist nurse or student doctor, took 20 
minutes which may be considered feasible in routine pre-operative assessment 
clinics.  
 
A retrospective pooled analysis of 83 patients over the age of 70 enrolled into a 
GINECO group study assessing Carboplatin and Cyclophosphamide (CC) [78] 
and a further 75 patients over the age of 70 enrolled into a subsequent study 
evaluating Carboplatin and Paclitaxel (CP) was performed to provide a 
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multivariate analysis of predictive factors for survival in older patients [79]. 
Elements of a geriatric assessment were performed at baseline including Mini-
mental state examination (MMSE, regarding a score > 24/30 as normal), 
polypharmacy, patient dependence as well as ECOG PS and baseline routine 
blood tests. In the CP group, a Hospital Anxiety and Depression score (HADS) 
and Instrumental Activities of Daily Living Score (IADLS) were also performed. 
75% of patients in the CC group and 68% in the CP group completed the 
planned 6 cycles of chemotherapy without severe toxicity. The only reported 
statistically significant prognostic factor for overall survival was the presence of 
depressive symptoms at baseline. No specific predictive factors for toxicity 
including age and ECOG PS were determined. 
 
A further study from the same group led to the development of the Geriatric 
Vulnerability Score (GVS)[80]. 111 patients with a median age of 79 (range 71-
93, 41% of whom were over the age of 80) and a diagnosis of advanced 
epithelial ovarian cancer received single-agent Carboplatin at AUC5.  74% of 
patients completed the planned 6 cycles; 10 patients stopped treatment early 
due to toxicity and 5 patients subsequently died from toxicity-related 
complications.   The GVS survival score developed retrospectively is a sum of 
five covariates (ADL, IADL, Lymphopenia, HADS (Hospital Anxiety and 
Depression scale) and hypoalbuminaemia)) each assigned a value of one.  A 
deficit in 3 or more covariates resulted in a risk ratio of mortality of 2.94 
(p=0.0006).  This cut–off, also discriminated two groups with significantly 
different treatment completion, severe adverse events and unplanned hospital 
admissions rates [80].  The GINECO group are currently recruiting to a 
prospective phase 2 study evaluating standard 3 weekly dosing of Carboplatin 
and Paclitaxel, single-agent Carboplatin (AUC 5 or 6) every 3 weeks and dose 
dense weekly Carboplatin (AUC2) and weekly Paclitaxel (60mg/m2) in patients 
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over the age of 70 with a GVS score of ≥ 3 (NCT02001272).  To date, there are 
no clinical studies evaluating the role of GA in endometrial, cervical cancer or 
recurrent ovarian cancer. 
 
A prospective cohort study, GOG-0273 [81], evaluated the role of geriatric 
assessment to predict toxicity to one of two regimens, single-agent carboplatin or 
carboplatin/paclitaxel (patient and physician’s choice) as first line therapy. In this 
study, rates of completion of 4 cycles of chemotherapy were higher in the 
combination cohort (92% combination arm vs. 75% single agent). Overall, the 
patients in the combination cohort were younger (mean age 73 versus 83) and 
fitter (PS 2 or 3 11% combination arm versus 37% single agent). In this study, 
IADL was not found to correlate with tolerance to chemotherapy. However, 
limitation in social activities was significantly associated with reduced 
chemotherapy tolerance.  A 3rd arm consisting of weekly Paclitaxel has been 
added and is currently recruiting. 
 
 
Biological markers of frailty 
 
The development of biological markers of frailty that have the ability to 
successfully differentiate between older patients who are fit for cancer therapies 
and those who are more at risk, predict toxicity and survival outcomes is much 
needed.  This area remains relatively under studied but some of the potential 
biomarkers will be discussed here. 
 
IL-6 has been shown to be independently associated with increased rates of 
cognitive impairment and steeper cognitive decline in a study of elderly patients 
(median age 75) with a history of cardiovascular disease [82].  CRP, IL-6 and IL-
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1RA have also been shown to be associated with worse physical performance in 
a prospective Italian study of  over a thousand  older participants [83].  The 
Women’s Health and Ageing (WHAS 1) study demonstrated that the presence of 
high levels of IL-6 and low levels of insulin-like growth factor (IGF1) in a 
population of women aged 65 years or more with moderate or severe disability 
were associated with an increase in 5 year mortality [84]. So far, the significance 
of the above markers in older cancer patients is not known. 
 
Telomeres are short segments of DNA at the end of chromosomes, which, with 
each successive mitotic division shorten by a process of telomerisation to reduce 
the risk of replication errors and therefore maintain DNA integrity.  Causes of 
oxidative stress such as smoking may increase the rate of telomere loss.  This 
has led investigations as to whether telomere length may be a marker of 
“biological age” rather than chronological.  Short telomere length has been 
associated with several diseases of ageing such as cardiovascular disease [85] 
but has yet to be consistently associated with increased mortality in older 
patients [86, 87].  Shorter telomere length has been associated with reduced 
survival from soft tissue, breast, lung and colorectal cancer [88-92]. 
 
Two studies have explored the potential significance of telomere length in 
ovarian cancer. The first study used PCR-based techniques to assess telomere 
length from peripheral blood leucocytes in 1042 women with a diagnosis of 
ovarian cancer from the Ontario Cancer Registry. No correlation between relative 
telomere length and ovarian cancer survival was noted (p=0.55) [93].  However, 
the GINECO group recently reported that in older patients with ovarian cancer, 
shorter telomere length was associated with increased chemotherapy related 
toxicity, increased unplanned hospital admissions, serious adverse events and 
grade 3-4 non-haematological toxicity. Shorter telomere length was also 
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associated with an increased risk of premature death [94]. Further studies in this 
area are warranted to clarify the clinical relevance. 
 
The secretion of cytokines/chemokines and soluble factors such as cathelin-
related antimicrobial peptide (CRAMP) and Chitenases [95] have also been 
shown to be associated with replicative senescence.   It remains to be seen 
whether a single frailty biomarker or indeed a panel of biomarkers adds any 
further information to either CGA or an abbreviated geriatric assessment.   
 
 
Steps to improving outcomes in older patients 
 
 
In an international study commissioned by the NCEI/POI collaboration, clinicians 
from a group of countries (UK, Canada, Sweden, Germany, Denmark and Spain) 
when asked via a questionnaire on the key factors used in order to be able to 
decide a patient’s fitness for systemic therapy reported that biological age, 
performance status and comorbidities were all more influential than chronological 
age. This is in contrast to the results seen from case studies submitted to the 
same audience where chronological age was seen to be the main determining 
factor on whether to subject a patient to higher intensity treatment. This suggests 
that, attitudes towards treating older patients are already in favour of assessing 
biologically rather than chronologically but in the absence of a proven, validated 
tool to predict frailty and toxicity from treatment, chronological age remains a 
crucial determinant of treatment decisions [96]. 
 
An ongoing lack of evidence in the area has led to the convening of an ASCO 
subcommittee in 2015 to develop recommendations to improve the evidence base for 
treating older adults with cancer [21].  These were fivefold: “(1) Use clinical trials to 
improve the evidence base for treating older adults with cancer, (2) leverage research 
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designs and infrastructure for generating evidence on older adults with cancer, (3) 
increase US Food and Drug Administration authority to incentivize and require research 
involving older adults with cancer, (4) increase clinicians’ recruitment of older adults with 
cancer to clinical trials, and (5) use journal policies to improve researchers’ reporting on 
the age distribution and health risk profiles of research participants”.  The importance of 
improving outcomes for older patients including women with gynaecological cancers is 
gaining international recognition and is a priority for oncology organisations including 
ESMO and ESGO.   
 
Better education of oncogeriatric issues for not only oncologists but all health care 
professionals involved in the multidisciplinary management of older patients is much 
needed. Not all cancer centres currently have the infrastructure and resources to refer all 
older cancer patients to a geriatric specialist department. A significant step would be 
working towards implementing the use of a GA tool in oncology clinics and cancer teams 
considering which interventions (e.g. occupational therapy, physiotherapy, polypharmacy 
management) are achievable in clinical practice currently and desired for the future.  
 
An internationally accepted consensus agreement on one CGA to be used for all older 
cancer patients is yet to be reached.  It may well be however that this is unattainable in the 
near future.  The impact of factors such as comorbidities and functional limitations on 
outcomes is likely to be influenced by the treatment modality and tumour type and 
therefore more than one tool may be applicable. A good starting point for both clinical 
practice and clinical trials is to include some form of GA.  The key domains to be evaluated 
when assessing older women with gynaecological malignancies for all treatment 
modalities are: 1. Function and mobility (as assessed by ADL, IADL, self-reported falls, 
“timed-up and go” test), 2. Comorbidities (e.g. Charlson comorbidity index or Cumulative 
illness rating scale – geriatrics, 3. Cognition (e.g. MMSE, min-COG), 4. Pyschological (e.g. 
Geriatric depression scale or hospital anxiety and depression scale), 5. Nutrition (e.g. mini-
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nutritional assessment,  BMI, serum albumin), 6. Performance status (ECOG PS, 
Karnovosky), Social support eg. (MOS social support survey)[65, 67].  Clinical trials in 
older patients should be encouraged to include a form of Geriatric Assessment. A 
challenge will be the application of results in clinical practice if multiple different GAs are 
utilised in different clinical trials.  
 
Prospective studies evaluating and validating the currently available screening/abbreviated 
geriatric scores as a risk prediction method for morbidity, toxicity and mortality from 
surgery, chemotherapy or radiotherapy would help to build the evidence base for the risk 
predicting ability of these tools in gynaecological malignancies and help rationalise which 
older patients should undergo full multidisciplinary CGA.   
 
The major gap in the current evidence base, continues to be whether or not undertaking 
full CGA including interventions and follow-through with a multidisciplinary team impacts 
on tolerance to treatment, survival or improved quality of life for older women with 
gynaecological malignancies.  Randomised, multi-centre prospective studies comparing 
current standard practice to including geriatric assessment and interventions in decision-
making are required. One of the challenges is the reproducibility of assessments and 
interventions.    
 
The endpoints of clinical studies specifically in older patients need to be considered. OS 
has been the gold standard endpoint for treatment trials but disease-specific survival 
should also be collected as death in older patients can be due to other diseases and 
toxicities. Functional dependency, toxicities (acute and chronic) and quality of life are 
being increasingly recognized as important outcomes specifically for the older population 
along with more conventional, ‘standard’ endpoints such as PFS and OS. ‘Active life’ 
expectancy (e.g caring for grandchildren, working) should also be recorded. Trials in older 
patients incorporating some of the above as composite and/or co-primary endpoints are 
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warranted[97] with the aim of then introducing these into future clinical trials irrespective of 
age so that appropriate sub-group analyses can be undertaken prospectively in older 
patients.  
 
Finally, the incorporation of biobanking patient material into prospective clinical studies 
involving older patients is essential to better understand the potential role these 
biomarkers may play. 
 
Conclusion 
 
There has been much progress in the development of both screening geriatric 
assessments and full comprehensive geriatric assessment in oncological patients 
over the past decade. However, full, Geriatrician-led CGA with follow-up has yet 
to be demonstrated to improve outcomes treating older patients with 
gynaecological cancers.  It also has significant resource implications and this has 
led to the interest in developing abbreviated geriatric assessments, primarily thus 
far, to attempt to risk stratify older patients into those who are likely to suffer from 
excess toxicity.  An ageing population and the rising incidence of gynaecological 
malignancies with increasing age means that all oncologists will be treating a 
population with a significant number of older, potentially frailer patients and 
expertise in geriatric oncology will be increasingly required for the majority of 
practicing oncologists. Further education is needed for oncologists in the 
assessment of older patients and the management of common issues affecting 
older patients that may impair their ability to tolerate cancer treatment and have 
long-term consequences.  The results of Elderly Women Ovarian Cancer 
(EWOC)-1 are eagerly awaited to better inform the first-line treatment of older 
patients. Given the majority of stage III and IV gynaecological cancer patients will 
relapse, there is an urgent need for studies in the recurrent setting. Finally, 
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collaboration and integration with geriatric experts are critical for the success of 
improving outcomes for older women with gynaecological malignancies.   
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Table 1. 
UK Age-specific relative survival at 1 and 5 years by tumour type 					
Study Inclusion 
Criteria 
Regimens assessed n Survival (PFS and 
OS) 
Key points 
GINECO [78] >70 years Stage III/IV 
Carboplatin/Cyclophospha
mide  
83 
 OS 21.6 months 
Post-hoc analysis. 
75% patients completed planned 6 cycles 
ECOG PS not predictive for survival 
Cancer Type 1-year age-specific relative survival 
(%) 
5-year age-specific relative survival (%) 
Cervical [6] 
50-59 years  85.2 59.1 
70-79 years 70.0 34.0 
Endometrial [98] 
55-59 years 95.6% 86.2 
75-79 years 86.5 67.7 
Ovarian [3] 
55-59 years 85.9 47.0 
75-79 years 56.6 24.5 
GINECO – 
Analysis of two 
consecutive trials 
[79] 
>70 years 
Stage III/IV Carboplatin/Paclitaxel 75 OS 25.9 months 
Prospective study. 
68% patients completed planned 6 cycles. 
Depressive symptoms at baseline predictive for OS 
AGO-OVAR [40] >70 years  
Carboplatin/Paclitaxel vs. 
Cisplatin/Paclitaxel 103 Not reported 
Post-hoc analysis.   
High proportion of PS 0/1 
No difference in quality of life 
Older patients more likely to discontinue treatment early 
despite comparable reported toxicity rates 
MITO-5 [43] >70 Stage IC-IV 
Dose-dense weekly 
Carboplatin/weekly 
Paclitaxel 
27 OS 32 months 
Prospective study. 
65% patients completed planned six cycles 
Favorable toxicity profile 
 
GINECO/GVS 
[80] 
>70 years 
Stage III/IV 
 
Carboplatin Monotherapy 
(AUC 5) 109 
PFS 9.2 months 
OS 17.4 months 
Prospective study. 
74% patients completed planned 6 cycles. 
Results have informed design of prospective study utilising 
GVS score 
GOG0273 [81] >70 years  
I: Carboplatin AUC5 and 
Paclitaxel 135mg/m2 or 
II: Carboplatin AUC 5 3 
weekly for 4 cycles 
208 Not yet reported 
Prospective study. 
Physicians choice of regimen I or II 
IADL not associated with ability to complete chemotherapy 
without delay or dose reduction 
Limitation of social activities associated with decreased 
tolerance to chemotherapy 
3rd arm of weekly Paclitaxel added; results awaited. 	
Table 2. Abbreviated geriatric assessment tools 
 
Abbreviations: ADL, activities of daily living; MNA-SF, mini-nutritional assessment short form; BP, blood pressure, IADL, instrumental activities of 
daily living; LDH, lactate dehydrogenase; MMSE, mini mental state examination; MNA, mini nutritional assessment; BMI, body mass index; HADS, 
hospital anxiety and depression scale 				
GA Tool Domains assessed Comments 
C-SGA. 
SAKK cancer-
specific geriatric 
assessment [99] 
 
 
 
Age-adjusted Charlson Comorbidity Index (CCI) 
Vulnerable Elders Survey (VES-13) 
Geriatric Depression Score (GDS-5) 
Modified MOS – Social Support Survey (mMOS-SS) 
Mini-Cog 
Feasibility study. Mean time for pt. to complete questionnaire - 17.33 ± 
7.34 vs. 20.59 ± 6.53 minutes for physicians 
No biochemical/laboratory based parameters 
No assessment of correlation between toxicity/mortality, only feasibility of 
completion. 
GAH. 
Geriatric 
Assessment in 
Hematology [100]. 
 
 
 
Number of drugs 
Gait speed 
Depression score (single-question) 
3 ADL questions (from VES-13) 
Subjective health status 
4 items from MNA-SF (BMI, Weight loss during last 3 months, 
food intake decline over past 3 months, psychological 
stress/acute disease 
SPMSQ (short portable mental status questionnaire) 
Prognostic index for 4-year mortality in Older adults 
363 patients newly diagnosed with haematological malignancies. 
Internally validated and reproducible. 
Not validated in solid-organ malignancies 
Mean time to complete 11.9 +/- 4.7 min 
 
 
CRASH 
The chemotherapy 
Risk Assessment 
Scale for High-Age 
patients [25] 
Haematological Toxicity: 
Diastolic BP 
IADL 
LDH 
Chemotox score (scoring System 0-2 based on relative 
toxicity; for example, carboplatin/pemetrexed = 1) 
 
Non-Haematological Toxicity: 
ECOG Performance status 
MMSE 
MNA 
Chemotox score 
460 patients.  
Valid across a large number of chemotherapy regimens 
Incorporation of potential toxicity of treatment into the risk scoring (MAX2 
index). 
Predictive for toxicity 
 
 
G8 [68] 
 
Nutritional (derived from MNA) 
Weight loss during last 3 months 
Mobility 
Neuropsychological/Dementia 
BMI 
Polypharmacy (>3 drugs/day) 
Patient comparison of health status compared to others of 
their age 
Age 
Validated first as a surrogate for CGA.  
202 patients over the age of 65 included with self-completed 
questionnaires across all tumour types. 
Patients with a low G8 score of ≤14 were more likely to experience severe 
chemotherapy toxicity than those with a high G8 score: 64.6% vs.46.9% 
(χ2=5.029, p=0.025) 
CARG [63]  1. Age: > 72 years 
2. Cancer type: GI or genitourinary 
3. No of chemotherapy drugs: polychemotherapy 
4. Chemotherapy dosing: standard dose 
5. Hemoglobin: <11 g/dL (male); <10 g/dL (female) 
6. Creatinine clearance: <34 mL/min (Jelliffe, ideal weight) 
7. Hearing: fair or worse 
8. No of falls in the last 6 months: ≥	1 
9. IADL: taking medications with some help or unable to take 
medication 
10. Walking one block: somewhat limited or limited a lot 
11. Decreased social activity because of physical and/or 
emotional health: 
Predictive score derived from prospective analysis of 500 patients over 
the age of 65 with various cancers. 
Mean age 73. 
Low (0-5) Intermediate (6-9) and High (10-19). 
Predictive for chemotherapy related toxicity. 
 
 
GVS/GINECO[80] Age 
ECOG Performance status 
Hypoalbuminaemia 
Lymphopaenia 
Functional: ADL, IADL 
Depression: HADS 
Predictive for chemotherapy related toxicity. 
Deficit in 3 or more covariates results in a RR of mortality of 2.94. 
 
	
Table 3. Chemotherapy studies in the elderly population 
 
Abbreviations:  AUC, area under the curve; ECOG PS, eastern cooperative oncology group performance status; OS, overall survival; PFS, progression-free 
survival; GVS, geriatric vulnerability score; IADL, instrumental activities of daily living			
